What Kodiak Sciences’ Recent Moves Mean For Investors

Kodiak Sciences (KOD), a clinical stage retinal drug developer, has been on investors’ radar following recent share price swings, including a 3.5% gain over the past day and a mixed pattern over the past week and month.

Beyond the latest moves, Kodiak Sciences’ 1 month share price return of 11.63% and very large 1 year total shareholder return suggest recent momentum follows a much stronger rebuilding of investor expectations after earlier long term losses. At the latest share price of $25.72, each swing reflects how the market is reassessing both the company’s clinical progress and the risks still attached to a business that remains in the development stage.

If you’re watching Kodiak and considering where else growth stories might emerge in healthcare, it could be a good time to scan our list of 32 healthcare AI stocks as another source of ideas.

With Kodiak’s shares up 11.63% over the past month, trading at $25.72 and showing a very large 1 year total return, the key question now is whether the stock still trades at a discount or if the market is already pricing in future growth.

Discounted Cash Flow Suggests A Large Gap To Fair Value

Our DCF model currently points to a fair value of $80.15 for Kodiak Sciences, compared with the latest share price of $25.72, which indicates the stock screens as heavily undervalued on this basis.

The SWS DCF model works by estimating future cash flows the business could generate and then discounting them back to today using a required rate of return. For a company like Kodiak that is still in the clinical stage with minimal current revenue and ongoing losses of $217.336m, this approach focuses on what the pipeline might produce over time rather than what the income statement shows right now.

Because Kodiak is a development stage biotech with no meaningful revenue reported and is expected to remain unprofitable for at least the next three years, any DCF estimate is highly sensitive to long term assumptions about clinical success, commercialization timing and eventual margins. That is why you often see a wide gap between a DCF output and the current share price in this part of the healthcare sector.

Result: DCF fair value of $80.15 (UNDERVALUED)

However, Kodiak’s ongoing loss of $217.336m and its dependence on successful outcomes for multiple retinal drug candidates mean that clinical or regulatory setbacks could quickly challenge this optimism.

Another Angle On Kodiak’s Valuation

While our DCF model suggests Kodiak looks heavily undervalued, the P/B ratio tells a very different story. At 67.3x book value versus 10.1x for peers and 2.7x for the wider US biotechs group, Kodiak screens as very expensive on this measure. For you as an investor, that gap points to meaningful valuation risk if sentiment or expectations change. Which signal do you treat as more important right now: long term cash flow potential, or today’s balance sheet multiple?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kodiak Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals so far leave you undecided, this is the moment to look at the numbers yourself and act on your own judgment. To help you weigh both the concerns and the upside that investors see, take a closer look at the 1 key reward and 4 important warning signs.

Ready to find your next idea?

If Kodiak has caught your eye, do not stop here. The real edge comes from comparing opportunities side by side and spotting patterns across different types of companies.

• Target steadier profiles by scanning 63 resilient stocks with low risk scores that may suit you if capital protection sits high on your priority list.
• Hunt for quality at a sensible price by checking 46 high quality undervalued stocks that currently screen as trading below their estimated worth.
• Spot potential future standouts with our screener containing 23 high quality undiscovered gems before they sit on every investor’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.